biotech / news / / Reuters
The San Diego-based biotech is exploring the joint spin-off of the drug, INBRX-106, and a second experimental cancer treatment.
Inhibrx is considering jointly spinning off INBRX-106 and ozekibart, potentially worth over $9 billion.
KEY POINTS
- Ozekibart has shown a 52% tumor shrinkage rate in Ewing sarcoma patients in one study.
- INBRX-106’s valuation depends on its ability to enhance Keytruda efficacy in ongoing clinical trials.
- Inhibrx is expected to announce interim INBRX-106 trial results and ozekibart FDA filing next month.
- Merck's strategic need for INBRX-106 arises as Keytruda faces 2028 patent expirations and biosimilar competition.
COMPANIES
Summarized by Newsio from Reuters. How we summarize →